Published online before print November 4, 2004, doi: 10.1161/01.RES.0000149571.96304.36
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Submitted on August 4, 2004
Revised on October 18, 2004
Accepted on October 25, 2004
Xanthine Oxidoreductase Is an Endogenous Regulator of Cyclooxygenase-2
Toshio Ohtsubo ;
From the Cardiovascular Branch (T.O., I.I.R., T.F.) and Transgenic Core Facility (C.L.), National Heart, Lung, and Blood Institute, NIH, Bethesda, Md; and Division of Veterinary Resources (M.F.S.), OD, NIH, Bethesda, Md.
* To whom correspondence should be addressed. E-mail: finkelt{at}nih.gov.
Xanthine oxidoreductase (XOR) is the enzyme responsible for the final step in purine degradation resulting in the generation of uric acid. Here we have generated mice deficient in XOR. As expected, these animals lack tissue XOR activity and have low to undetectable serum levels of uric acid. Although normal at birth, XOR-/- mice fail to thrive after 10 to 14 days, and most die within the first month. The cause of death appears to be a form of severe renal dysplasia, a phenotype that closely resembles what has been observed previously in cyclooxygenase-2 (COX-2)-deficient mice. We further demonstrate that in the first month of life, a period in which the mouse kidney is undergoing rapid maturation and remodeling, wild-type mice exhibit an 
30-fold increase in renal XOR activity, with a corresponding induction of COX-2 expression. In contrast, during this same period, XOR-/- animals fail to augment renal COX-2 expression. Finally, we show that in vitro and in vivo, uric acid can stimulate basal COX-2 expression. These results demonstrate that XOR activity is an endogenous physiological regulator of COX-2 expression and thereby provide insight into previous epidemiological evidence linking elevated serum uric levels with systemic hypertension and increased mortality from cardiovascular diseases. In addition, these results suggest a novel molecular link between cellular injury and the inflammatory response.
Key words: kidney • cyclooxygenase
This article has been cited by other articles:
 |
|
 |
|
  T. Ohtsubo, K. Matsumura, K. Sakagami, K. Fujii, K. Tsuruya, H. Noguchi, I. I. Rovira, T. Finkel, and M. Iida Xanthine Oxidoreductase Depletion Induces Renal Interstitial Fibrosis Through Aberrant Lipid and Purine Accumulation in Renal Tubules Hypertension, October 1, 2009; 54(4): 868 - 876. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Jeong, A. U. Rao, J. Xu, S. L. Ogg, Y. Hathout, C. Fenselau, and I. H. Mather The PRY/SPRY/B30.2 Domain of Butyrophilin 1A1 (BTN1A1) Binds to Xanthine Oxidoreductase: IMPLICATIONS FOR THE FUNCTION OF BTN1A1 IN THE MAMMARY GLAND AND OTHER TISSUES J. Biol. Chem., August 14, 2009; 284(33): 22444 - 22456. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Lin, P. Xu, P. LaVallee, and J. R. Hoidal Identification of Proteins Binding to E-Box/Ku86 Sites and Function of the Tumor Suppressor SAFB1 in Transcriptional Regulation of the Human Xanthine Oxidoreductase Gene J. Biol. Chem., October 31, 2008; 283(44): 29681 - 29689. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Boueiz, M. Damarla, and P. M. Hassoun Xanthine oxidoreductase in respiratory and cardiovascular disorders Am J Physiol Lung Cell Mol Physiol, May 1, 2008; 294(5): L830 - L840. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Terao, M. Kurosaki, M. M. Barzago, E. Varasano, A. Boldetti, A. Bastone, M. Fratelli, and E. Garattini Avian and Canine Aldehyde Oxidases: NOVEL INSIGHTS INTO THE BIOLOGY AND EVOLUTION OF MOLYBDO-FLAVOENZYMES J. Biol. Chem., July 14, 2006; 281(28): 19748 - 19761. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. J. Seymour, L. E. Roberts, M. A. Fini, L. A. Parmley, T. L. Oustitch, and R. M. Wright Stress Activation of Mammary Epithelial Cell Xanthine Oxidoreductase Is Mediated by p38 MAPK and CCAAT/Enhancer-binding Protein-beta J. Biol. Chem., March 31, 2006; 281(13): 8545 - 8558. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Ardanaz and P. J. Pagano Hydrogen peroxide as a paracrine vascular mediator: regulation and signaling leading to dysfunction. Experimental Biology and Medicine, March 1, 2006; 231(3): 237 - 251. [Abstract] [Full Text] [PDF]
|
|